Sanofi (SNY) Upgraded by Barclays PLC to “Equal Weight”

Barclays PLC upgraded shares of Sanofi (NYSE:SNY) from an underweight rating to an equal weight rating in a research note released on Wednesday morning, MarketBeat.com reports.

A number of other research analysts have also weighed in on SNY. Zacks Investment Research lowered Sanofi from a hold rating to a strong sell rating in a report on Friday, October 6th. BidaskClub lowered Sanofi from a hold rating to a sell rating in a report on Monday, July 24th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of Sanofi in a report on Friday, September 15th. Cowen and Company reaffirmed a market perform rating and set a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, Argus reaffirmed a buy rating and set a $55.00 price objective on shares of Sanofi in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $53.50.

Shares of Sanofi (NYSE:SNY) opened at $44.54 on Wednesday. Sanofi has a 52 week low of $38.45 and a 52 week high of $50.65. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $112,307.97, a P/E ratio of 14.05, a PEG ratio of 2.46 and a beta of 0.88.

ILLEGAL ACTIVITY NOTICE: “Sanofi (SNY) Upgraded by Barclays PLC to “Equal Weight”” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/19/sanofi-sny-upgraded-by-barclays-plc-to-equal-weight.html.

In other news, major shareholder Sanofi bought 105,820 shares of the stock in a transaction on Thursday, August 24th. The shares were bought at an average price of $482.04 per share, with a total value of $51,009,472.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.00% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fisher Asset Management LLC boosted its stake in shares of Sanofi by 3.3% during the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after acquiring an additional 443,799 shares during the last quarter. Founders Financial Securities LLC acquired a new stake in shares of Sanofi during the second quarter valued at $907,000. Goodwin Daniel L acquired a new stake in shares of Sanofi during the second quarter valued at $239,000. AMG National Trust Bank boosted its stake in shares of Sanofi by 5.3% during the second quarter. AMG National Trust Bank now owns 51,423 shares of the company’s stock valued at $2,464,000 after acquiring an additional 2,594 shares during the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after acquiring an additional 875 shares during the last quarter. 9.36% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply